Stay updated on Sparsentan in IgA Nephropathy: Clinical Trial
Sign up to get notified when there's something new on the Sparsentan in IgA Nephropathy: Clinical Trial page.

Latest updates to the Sparsentan in IgA Nephropathy: Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study information regarding the PROTECT study for Immunoglobulin A Nephropathy, which included key aspects such as study design, patient criteria, and investigational drug details. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference24%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.8%
Stay in the know with updates to Sparsentan in IgA Nephropathy: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sparsentan in IgA Nephropathy: Clinical Trial page.